Clinical trial
Study Evaluating RGH-188 in the Treatment of Patients With Schizophrenia
NCT00404573 · Forest Laboratories, Industry · Completed
Key facts
| NCT number | NCT00404573 |
|---|---|
| Title | Study Evaluating RGH-188 in the Treatment of Patients With Schizophrenia |
| Official title | A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of RGH-188 in the Acute Exacerbation of Schizophrenia |
| Lead sponsor | Forest Laboratories, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | RGH-188 |
| Enrollment | 375 |
| Start date | Nov 1, 2006 |
| Primary completion | Aug 1, 2007 |
| First posted | Nov 29, 2006 |
| Last update posted | Jan 7, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: